In March 2025, the company declared new options for a direct-to-buyer presenting of its Wegovy weight loss drug. The company proven a new pharmacy, called NovoCare, which would demand clients $499 monthly for use of the drug, under half the price of the drug by way of other pharmaceutical distribution networks.[fifty three]Research of Rybelsus and